Osteoarthritis, KneePhase 4NCT05058209
Effect of ZILRETTA Versus CELESTONE on Quality of Life, Pain, Neuromuscular Function, and Physical Performance
A Phase 4 study testing Triamcinolone acetonide extended-release injectable suspension and Betamethasone sodium phosphate and betamethasone acetate Injectable Suspension in people with Osteoarthritis, Knee, run by ROC Foundation at 1 site in United States.
Trial summary
The purpose of this study is to examine the pre, post, and follow up effects of a single ZILRETTA knee injection vs a single CELESTONE SOLUSPAN knee injection on physiological measure of self-reported quality of life, pain, physical function, and physical performance in individuals with osteoarthritis (OA) knee pain. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Osteoarthritis, Knee
- What is being tested?
- Triamcinolone acetonide extended-release injectable suspension and Betamethasone sodium phosphate and betamethasone acetate Injectable Suspension
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- 1 siteUnited States
- Study dates
- 30 Nov 2020to 28 Apr 2021
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Men and women age 18 years or older with symptomatic bilateral knee OA
- Symptomatic knee OA will be defined as the presence of a definite osteophyte or joint space narrowing (KL Grade ≥2) on posteroanterior (PA) fixed flexion knee radiographs in subjects limited by bilateral pain rated on a Numerical Rating Scale as ≥ 4/10 on more than half of the days over the past month. Radiographic change must be visible at standard image size, irrespective of capability to detect more subtle changes through digital enhancement.
- Bilateral knee symptoms for ≥ 3 months prior to screening
- Has undergone at least one prior conservative osteoarthritis treatment (e.g. Physical therapy, analgesics)
- Ambulatory
- Willing and able to comply with the study procedures and visit schedules and ability to follow verbal and written instructions.
Who cannot join
- Current consumption of more than 14 alcoholic drinks per week
- Clinical signs and symptoms of active knee infection or crystal disease of either knee within 1 month of screening
- Diagnosed with rheumatoid arthritis, Reiter's syndrome, psoriatic arthritis, gout, ankylosing spondylitis, or arthritis secondary to other inflammatory diseases; HIV, viral hepatitis; chondrocalcinosis, Paget's disease, or villonodular synovitis
- Diagnosed with leukemia, known presence of metastatic malignant cells, or ongoing or planned chemotherapeutic treatment.
- A gout attack in the past 2 years.
- Diseases of the spine, hip or other lower extremity joints judged by the investigator to be contributing to the pain in either knee (i.e. sciatica, nerve pain, hip OA). Note: Patients with hip replacement in either hip may be enrolled provided there is sufficient pain relief after hip replacement that analgesics are not required.
Show all 20Show fewer
- Untreated symptomatic injury of either knee (e.g., acute traumatic injury, anterior cruciate ligament injury, clinically symptomatic meniscus injury characterized by a mechanical issue such as locking or catching).
- Uncontrolled diabetes (HbA1c >7.2)
- Women who report pregnancy or childbearing potential and not using acceptable contraceptive measures (oral contraceptive, long acting reversible contraceptive therapy) (due to the potential for change in body mass and distribution to alter knee symptoms over the period of follow-up).
- Presence of surgical hardware or other foreign body intended to treat arthritis or cartilage-related pathology in either knee.
- Arthroscopy or open surgery of either knee within 6 months of screening.
- Planned/anticipated surgery of either knee during the study period.
- Use of systemic immunosuppressant within 6 weeks of screening.
- Oral corticosteroids (investigational or marketed) within 2 weeks of screening (unless on chronic stable dose for >3 months).
- IA corticosteroid (investigational or marketed) in either knee within 3 months of screening.
- IV or IM (Intramuscular) Corticosteroid injection (investigational or marketed) within 3 months of screening.
- Any other IA drug/biologic use within 6 months of screening or 5 half-lives (whichever is longer) (e.g., hyaluronic acid, platelet-rich plasma (PRP) injection, stem cells, prolotherapy and amniotic fluid injection).
- Any documented clinically significant degree of cognitive impairment or other condition, finding, or psychiatric illness at screening which, in the opinion of the investigator, could compromise subject safety.
- Any condition other than OA of the knee which, in the opinion of the investigator, affects the ability to ambulate to a sufficient degree to interfere with the assessment of the safety and treatment effects of the study injection.
- Participated in any interventional drug or device trial within 30 days prior to screening or concurrent participation in another research study that could complicate interpretation of the study findings.
Trial locations and contacts
1 site in 1 country.
About this study
The purpose of this study is to examine the pre, post, and follow up effects of a single ZILRETTA knee injection vs a single CELESTONE SOLUSPAN knee injection on physiological measure of self-reported quality of life, pain, physical function, and physical performance in individuals with osteoarthritis (OA) knee pain. The Primary Investigator (PI) will recruit 20 symptomatic knee OA patients for this study. Patients will be randomized into one of two treatment arms, Arm 1 (ZILRETTA injection) or Arm 2 (CELESTONE SOLUSPAN injection). Patients in Arm 1 will receive a single 5 mL IV injection of 32 mg ZILRETTA into the affected knee joint. Patients in Arm 2 will receive a 5ml IV injection of 6mg/ml CELESTONE SOLUSPAN into the affected knee joint. Each study arm will include 10 patients. All data will be collected prior to injection (baseline), as well as at 6-week (post 1) and 12-week follow-ups (post 2). Patients will blinded to treatment arm until after they complete their 12-week follow up.
Read the detailed description
Individuals with knee osteoarthritis (OA) often experience pain and difficulty completing many everyday activities, such as walking or climbing stairs. It is a major cause of lost work time and a serious disability for many people. Although there is no cure for arthritis, there are many treatment options available to help manage pain and keep people active.
The ZILRETTA knee injection and CELESTONE knee injection are both FDA approved, extended-release corticosteroid, and are both common nonsurgical treatment options for patients with OA. Currently, there are no studies that have compared ZILRETTA and CELESTONE SOLUSPAN.
- Aims Specific Aim 1: To determine the difference between intra-articular (IA) injection of Zilretta and intra-articular injection of Celestone in patients with knee OA improves physical performance (OARSI recommended physical performance measures).
Primary Hypothesis 1: Patients who receive knee IA injection of Zilretta or Celestone experience improved physical performance detectable at 6 weeks and 12 weeks.
Specific Aim 2: To determine the difference between IA injection of Zilretta and IA injection of Celestone in patients with knee OA improves physical function (KOOS-PF).
Hypothesis 2: Patients who receive knee IA injection of Zilretta or Celestone report improved patient-reported physical function (KOOS-PS) at 6 weeks and 12 weeks.
Specific Aim 3: To determine the difference between knee IA injection of Zilretta or Celestone in patients with knee OA improves quality of life (KOOS-QoL).
Hypothesis 3: Patients who receive knee IA injection of Zilretta or Celestone report improved quality of life (KOOS-QoL) detectable at 6 weeks and 12 weeks.
Specific Aim 4: To determine the difference between knee IA injection of Zilretta or Celestone in patients with knee OA improves pain based on numeric pain rating scale.
Hypothesis 3: Patients who receive knee IA injection of Zilretta or Celestone report improved pain level detectable at 6 weeks and 12 weeks.
II. Research Plan and Design
- Study Objective The goal of this study is to evaluate the efficacy of Zilretta compared to Celestone for improving quality of life, pain, neuromuscular function, and physical performance.
- Study Design The proposed study will compare Zilretta and Celestone effectiveness on patient-reported outcomes (quality of life, neuromuscular functioning, and pain) and physical performance (30-second chair standing test, 40m fast-paced walking test, stair ascent) related to knee arthritis. Patients will be chosen based on the level of arthritis of the knee and interest in non-surgical treatment options. After informed consent but before injection, Patients will be randomized into Zilretta or Celestone treatment arms. Patients will be consented and seen at baseline, in clinic at 6-weeks, and phone call follow-up at 12-weeks. Demographic information as well as any comorbidity or adverse events related to poor healing will be recorded.
Baseline
After completing informed consent but prior to injection, patients will complete:
- OARSI recommended physical performance tests (30-second chair standing test, 40m fast-paced walking test, stair ascent)
- KOOS-PS (Physical Function Shortform) - 7 questions
- KOOS-Quality of life subscale (QoL) - 4 questions
- Numerical Rating Scale (NRS) 6-week (Post 1)
During the 6-week follow up visit with the PI, patients will complete:
- OARSI recommended physical performance tests (30-second chair standing test, 40m fast-paced walking test, stair ascent) 12 weeks after treatment
- KOOS-PS (Physical Function Shortform) - 7 questions
- KOOS-Quality of life subscale (QoL) - 4 questions
- Numerical Rating Scale (NRS) 12-week (Post 2)
At 12-weeks post-injection, the Clinical Research Coordinator (CCRC) or Research Assistant (RA) will call each patient and patients will complete:
- KOOS-PS (Physical Function Shortform) - 7 questions
- KOOS-Quality of life subscale (QoL) - 4 questions
- Numerical Rating Scale (NRS)
If patients indicate any adverse events, high levels of pain, or have medical questions, the CCRC or RA will schedule the patient to be seen by the PI.
- Conditions
- Osteoarthritis, Knee
- Being tested
- Triamcinolone acetonide extended-release injectable suspension, Betamethasone sodium phosphate and betamethasone acetate Injectable Suspension
- Medical subject headings
- Osteoarthritis, Knee
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Triamcinolone acetonide extended-release injectable suspensionDrug
Also called Zilretta
Zilretta (Triamcinolone acetonide extended-release injectable suspension) is indicated as an intra-articular injection for the management of pain due to knee OA. The most commonly reported adverse reactions (incidence ≥1%) in clinical studies included sinusitis (2%), cough (2%), contusions (2%) and joint swelling (3%). For additional details, please see Package Insert (http://www.zilrettalabel.com/PI.pdf). The website for Zilretta additionally lists: joint pain, headache, back pain, sore throat and runny nose, and bruising as common side effects of receiving a Zilretta injection.
Betamethasone sodium phosphate and betamethasone acetate Injectable SuspensionDrug
Also called Celestone
Celestone (betamethasone sodium phosphate and betamethasone acetate Injectable Suspension, USP 6 mg per mL) is indicated as an intra-articular injection for the management of chronic or long-term inflammation associated with multiple conditions including severe allergies, dermatological diseases, endocrine disorders, gastrointestinal diseases, hematologic disorders, neoplastic diseases, nervous system disorders, ophthalmologic diseases, renal diseases, respiratory diseases and rheumatic disorders, and others that may not be listed. Celestone Soluspan is available in generic form. The most commonly reported adverse reactions include acne, increased hunger, and weight gain.
| Study group | Role | What they receive |
|---|---|---|
| Arm 1 | Active comparator | Triamcinolone acetonide extended-release injectable suspension. Single intra-articular extended-release injection of triamcinolone acetonide, to deliver 32 mg (5 mL). For intra-articular use only and should not be administered by the following routes: epidural, intrathecal, intravenous, intraocular, intramuscular, intradermal, subcutaneous. Receives: Drug: Triamcinolone acetonide extended-release injectable suspension |
| Arm 2 | Active comparator | Betamethasone sodium phosphate and betamethasone acetate Injectable Suspension, USP 6 mg per mL, 3 mg per milliliter betamethasone, as betamethasone sodium phosphate, and 3 mg per milliliter betamethasone acetate. When oral therapy is not feasible, the Injectable Suspension is indicated for intramuscular use only. Receives: Drug: Betamethasone sodium phosphate and betamethasone acetate Injectable Suspension |
What is being measured
The primary outcome is the main question the study is designed to answer.
OARSI - 30-second Chair Stand
The maximum number of chair stand repetitions possible in a 30 second period (2-4).
Measured: Baseline (removed due to COVID)
OARSI - 30-second Chair Stand
The maximum number of chair stand repetitions possible in a 30 second period (2-4).
Measured: 6 week (removed due to COVID)
OARSI - 30-second chair standing test
The maximum number of chair stand repetitions possible in a 30 second period (2-4).
Measured: 12 week (removed due to COVID)
OARSI - 40m Fast Paced Walk
A fast-paced walking test that is timed over 4 x 10m (33 ft) for a total 40 m (132 ft) (2).
Measured: Baseline (removed due to COVID)
OARSI - 40m Fast Paced Walk
A fast-paced walking test that is timed over 4 x 10m (33 ft) for a total 40 m (132 ft) (2).
Measured: 6 week (removed due to COVID)
OARSI - 40m Fast Paced Walk
A fast-paced walking test that is timed over 4 x 10m (33 ft) for a total 40 m (132 ft) (2).
Measured: 12 week (removed due to COVID)
OARSI - stair ascent
The time (in seconds) it takes to ascend and descend a flight of stairs (2-6). The number of stairs will depend on individual environmental situations. Where possible, the 9-step stair test with 20cm (8 inch) step height and handrail is recommended.
Measured: Baseline (removed due to COVID)
OARSI - stair ascent
The time (in seconds) it takes to ascend and descend a flight of stairs (2-6). The number of stairs will depend on individual environmental situations. Where possible, the 9-step stair test with 20cm (8 inch) step height and handrail is recommended.
Measured: 6 week (removed due to COVID)
OARSI - stair ascent
The time (in seconds) it takes to ascend and descend a flight of stairs (2-6). The number of stairs will depend on individual environmental situations. Where possible, the 9-step stair test with 20cm (8 inch) step height and handrail is recommended.
Measured: 12 week (removed due to COVID)
KOOS-PS (Physical Function Shortform)
Scoring: Never/none=0, Monthly/mild=1, Weekly/moderate=2, Daily/severe=3, Always/extreme=4. Calculate the mean score for the 11 items, and divide by the maximum possible score for each item (i.e. 4). Traditionally in orthopedics, 100 indicates no problems and 0 indicates extreme problems.
The normalized score is transformed to meet this standard. Please use the formula provided below. 100 - [(mean score PF1-PF11)/4 *100]
Measured: 6 week
KOOS-PS (Physical Function Shortform)
Scoring: Never/none=0, Monthly/mild=1, Weekly/moderate=2, Daily/severe=3, Always/extreme=4. Calculate the mean score for the 11 items, and divide by the maximum possible score for each item (i.e. 4). Traditionally in orthopedics, 100 indicates no problems and 0 indicates extreme problems.
The normalized score is transformed to meet this standard. Please use the formula provided below. 100 - [(mean score PF1-PF11)/4 *100]
Measured: Baseline
KOOS-PS (Physical Function Shortform)
Scoring: Never/none=0, Monthly/mild=1, Weekly/moderate=2, Daily/severe=3, Always/extreme=4. Calculate the mean score for the 11 items, and divide by the maximum possible score for each item (i.e. 4). Traditionally in orthopedics, 100 indicates no problems and 0 indicates extreme problems.
The normalized score is transformed to meet this standard. Please use the formula provided below. 100 - [(mean score PF1-PF11)/4 *100]
Measured: 12 week
KOOS-Quality of life subscale (QoL)
The KOOS's five patient-relevant dimensions are scored separately: Pain (nine items); Symptoms (seven items); ADL Function (17 items); Sport and Recreation Function (five items); Quality of Life (four items). A Likert scale is used and all items have five possible answer options scored from 0 (No problems) to 4 (Extreme problems) and each of the five scores is calculated as the sum of the items included. Scores are transformed to a 0-100 scale, with zero representing extreme knee problems and 100 representing no knee problems as common in orthopaedic scales and generic measures. Scores between 0 and 100 represent the percentage of total possible score achieved.
Measured: Baseline
KOOS-Quality of life subscale (QoL)
The KOOS's five patient-relevant dimensions are scored separately: Pain (nine items); Symptoms (seven items); ADL Function (17 items); Sport and Recreation Function (five items); Quality of Life (four items). A Likert scale is used and all items have five possible answer options scored from 0 (No problems) to 4 (Extreme problems) and each of the five scores is calculated as the sum of the items included. Scores are transformed to a 0-100 scale, with zero representing extreme knee problems and 100 representing no knee problems as common in orthopaedic scales and generic measures. Scores between 0 and 100 represent the percentage of total possible score achieved.
Measured: 6 week
KOOS-Quality of life subscale (QoL)
The KOOS's five patient-relevant dimensions are scored separately: Pain (nine items); Symptoms (seven items); ADL Function (17 items); Sport and Recreation Function (five items); Quality of Life (four items). A Likert scale is used and all items have five possible answer options scored from 0 (No problems) to 4 (Extreme problems) and each of the five scores is calculated as the sum of the items included. Scores are transformed to a 0-100 scale, with zero representing extreme knee problems and 100 representing no knee problems as common in orthopaedic scales and generic measures. Scores between 0 and 100 represent the percentage of total possible score achieved.
Measured: 12 week
Numerical Rating Scale (NRS)
patient to rate their pain on a defined scale. For example, 0-10 where 0 is no pain and 10 is the worst pain imaginable
Measured: Baseline
Numerical Rating Scale (NRS)
patient to rate their pain on a defined scale. For example, 0-10 where 0 is no pain and 10 is the worst pain imaginable
Measured: 6 week
Numerical Rating Scale (NRS)
patient to rate their pain on a defined scale. For example, 0-10 where 0 is no pain and 10 is the worst pain imaginable
Measured: 12 week
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Sep 2021
- Study start30 Nov 2020
- Primary completion28 Apr 2021
- Study completion28 Apr 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Osteoarthritis, KneeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Randomized and Controlled Blinded Clinical Trial
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 20 participants (actual)
Sponsor and investigators
- Lead sponsor
- ROC Foundation
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Sara C DePaoli, Study director, ROC FoundationTimothy J Bray, MD, Principal investigator, ROC Foundation
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05058209
- Sponsor's protocol ID
- 1657878
- Status last verified
- Sep 2021
- First submitted
- 7 Sep 2021
- Last updated
- 27 Sep 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 Sep 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of ZILRETTA Versus CELESTONE on Quality of Life, Pain, Neuromuscular Function, and Physical Performance
- ClinicalTrials.gov ID
- NCT05058209
- Acronym / sponsor ID
- 1657878
- Conditions
- Osteoarthritis, Knee
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 20 participants (actual)
- Lead sponsor
- ROC FoundationUniversity, hospital or other
- Study start
- 30 Nov 2020 (actual)
- Primary completion
- 28 Apr 2021 (actual)
- Study completion
- 28 Apr 2021 (actual)
- First posted
- 27 Sep 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to examine the pre, post, and follow up effects of a single ZILRETTA knee injection vs a single CELESTONE SOLUSPAN knee injection on physiological measure of self-reported quality of life, pain, physical function, and physical performance in individuals with osteoarthritis (OA) knee pain. The Primary Investigator (PI) will recruit 20 symptomatic knee OA patients for this study. Patients will be randomized into one of two treatment arms, Arm 1 (ZILRETTA injection) or Arm 2 (CELESTONE SOLUSPAN injection). Patients in Arm 1 will receive a single 5 mL IV injection of 32 mg ZILRETTA into the affected knee joint. Patients in Arm 2 will receive a 5ml IV injection of 6mg/ml CELESTONE SOLUSPAN into the affected knee joint. Each study arm will include 10 patients. All data will be collected prior to injection (baseline), as well as at 6-week (post 1) and 12-week follow-ups (post 2). Patients will blinded to treatment arm until after they complete their 12-week follow up.
Detailed description
Individuals with knee osteoarthritis (OA) often experience pain and difficulty completing many everyday activities, such as walking or climbing stairs. It is a major cause of lost work time and a serious disability for many people. Although there is no cure for arthritis, there are many treatment options available to help manage pain and keep people active.
The ZILRETTA knee injection and CELESTONE knee injection are both FDA approved, extended-release corticosteroid, and are both common nonsurgical treatment options for patients with OA. Currently, there are no studies that have compared ZILRETTA and CELESTONE SOLUSPAN.
- Aims Specific Aim 1: To determine the difference between intra-articular (IA) injection of Zilretta and intra-articular injection of Celestone in patients with knee OA improves physical performance (OARSI recommended physical performance measures).
Primary Hypothesis 1: Patients who receive knee IA injection of Zilretta or Celestone experience improved physical performance detectable at 6 weeks and 12 weeks.
Specific Aim 2: To determine the difference between IA injection of Zilretta and IA injection of Celestone in patients with knee OA improves physical function (KOOS-PF).
Hypothesis 2: Patients who receive knee IA injection of Zilretta or Celestone report improved patient-reported physical function (KOOS-PS) at 6 weeks and 12 weeks.
Specific Aim 3: To determine the difference between knee IA injection of Zilretta or Celestone in patients with knee OA improves quality of life (KOOS-QoL).
Hypothesis 3: Patients who receive knee IA injection of Zilretta or Celestone report improved quality of life (KOOS-QoL) detectable at 6 weeks and 12 weeks.
Specific Aim 4: To determine the difference between knee IA injection of Zilretta or Celestone in patients with knee OA improves pain based on numeric pain rating scale.
Hypothesis 3: Patients who receive knee IA injection of Zilretta or Celestone report improved pain level detectable at 6 weeks and 12 weeks.
II. Research Plan and Design
- Study Objective The goal of this study is to evaluate the efficacy of Zilretta compared to Celestone for improving quality of life, pain, neuromuscular function, and physical performance.
- Study Design The proposed study will compare Zilretta and Celestone effectiveness on patient-reported outcomes (quality of life, neuromuscular functioning, and pain) and physical performance (30-second chair standing test, 40m fast-paced walking test, stair ascent) related to knee arthritis. Patients will be chosen based on the level of arthritis of the knee and interest in non-surgical treatment options. After informed consent but before injection, Patients will be randomized into Zilretta or Celestone treatment arms. Patients will be consented and seen at baseline, in clinic at 6-weeks, and phone call follow-up at 12-weeks. Demographic information as well as any comorbidity or adverse events related to poor healing will be recorded.
Baseline
After completing informed consent but prior to injection, patients will complete:
- OARSI recommended physical performance tests (30-second chair standing test, 40m fast-paced walking test, stair ascent)
- KOOS-PS (Physical Function Shortform) - 7 questions
- KOOS-Quality of life subscale (QoL) - 4 questions
- Numerical Rating Scale (NRS) 6-week (Post 1)
During the 6-week follow up visit with the PI, patients will complete:
- OARSI recommended physical performance tests (30-second chair standing test, 40m fast-paced walking test, stair ascent) 12 weeks after treatment
- KOOS-PS (Physical Function Shortform) - 7 questions
- KOOS-Quality of life subscale (QoL) - 4 questions
- Numerical Rating Scale (NRS) 12-week (Post 2)
At 12-weeks post-injection, the Clinical Research Coordinator (CCRC) or Research Assistant (RA) will call each patient and patients will complete:
- KOOS-PS (Physical Function Shortform) - 7 questions
- KOOS-Quality of life subscale (QoL) - 4 questions
- Numerical Rating Scale (NRS)
If patients indicate any adverse events, high levels of pain, or have medical questions, the CCRC or RA will schedule the patient to be seen by the PI.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 2
- Model description
- Randomized and Controlled Blinded Clinical Trial
| Arm | Type | Receives |
|---|---|---|
| Arm 1 | Active comparator | Drug: Triamcinolone acetonide extended-release injectable suspensionTriamcinolone acetonide extended-release injectable suspension. Single intra-articular extended-release injection of triamcinolone acetonide, to deliver 32 mg (5 mL). For intra-articular use only and should not be administered by the following routes: epidural, intrathecal, intravenous, intraocular, intramuscular, intradermal, subcutaneous. |
| Arm 2 | Active comparator | Drug: Betamethasone sodium phosphate and betamethasone acetate Injectable SuspensionBetamethasone sodium phosphate and betamethasone acetate Injectable Suspension, USP 6 mg per mL, 3 mg per milliliter betamethasone, as betamethasone sodium phosphate, and 3 mg per milliliter betamethasone acetate. When oral therapy is not feasible, the Injectable Suspension is indicated for intramuscular use only. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Men and women age 18 years or older with symptomatic bilateral knee OA
- Symptomatic knee OA will be defined as the presence of a definite osteophyte or joint space narrowing (KL Grade ≥2) on posteroanterior (PA) fixed flexion knee radiographs in subjects limited by bilateral pain rated on a Numerical Rating Scale as ≥ 4/10 on more than half of the days over the past month. Radiographic change must be visible at standard image size, irrespective of capability to detect more subtle changes through digital enhancement.
- Bilateral knee symptoms for ≥ 3 months prior to screening
- Has undergone at least one prior conservative osteoarthritis treatment (e.g. Physical therapy, analgesics)
- Ambulatory
Key exclusion criteria (20 listed)
- Current consumption of more than 14 alcoholic drinks per week
- Clinical signs and symptoms of active knee infection or crystal disease of either knee within 1 month of screening
- Diagnosed with rheumatoid arthritis, Reiter's syndrome, psoriatic arthritis, gout, ankylosing spondylitis, or arthritis secondary to other inflammatory diseases; HIV, viral hepatitis; chondrocalcinosis, Paget's disease, or villonodular synovitis
- Diagnosed with leukemia, known presence of metastatic malignant cells, or ongoing or planned chemotherapeutic treatment.
- A gout attack in the past 2 years.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Triamcinolone acetonide extended-release injectable suspensionAlso: ZilrettaZilretta (Triamcinolone acetonide extended-release injectable suspension) is indicated as an intra-articular injection for the management of pain due to knee OA. The most commonly reported adverse reactions (incidence ≥1%) in clinical studies included sinusitis (2%), cough (2%), contusions (2%) and joint swelling (3%). For additional details, please see Package Insert (http://www.zilrettalabel.com/PI.pdf). The website for Zilretta additionally lists: joint pain, headache, back pain, sore throat and runny nose, and bruising as common side effects of receiving a Zilretta injection. | Drug | Arm 1 |
| Betamethasone sodium phosphate and betamethasone acetate Injectable SuspensionAlso: CelestoneCelestone (betamethasone sodium phosphate and betamethasone acetate Injectable Suspension, USP 6 mg per mL) is indicated as an intra-articular injection for the management of chronic or long-term inflammation associated with multiple conditions including severe allergies, dermatological diseases, endocrine disorders, gastrointestinal diseases, hematologic disorders, neoplastic diseases, nervous system disorders, ophthalmologic diseases, renal diseases, respiratory diseases and rheumatic disorders, and others that may not be listed. Celestone Soluspan is available in generic form. The most commonly reported adverse reactions include acne, increased hunger, and weight gain. | Drug | Arm 2 |
Primary outcome
OARSI - 30-second Chair Stand
Time frame: Baseline (removed due to COVID)
The maximum number of chair stand repetitions possible in a 30 second period (2-4).
OARSI - 30-second Chair Stand
Time frame: 6 week (removed due to COVID)
The maximum number of chair stand repetitions possible in a 30 second period (2-4).
OARSI - 30-second chair standing test
Time frame: 12 week (removed due to COVID)
The maximum number of chair stand repetitions possible in a 30 second period (2-4).
OARSI - 40m Fast Paced Walk
Time frame: Baseline (removed due to COVID)
A fast-paced walking test that is timed over 4 x 10m (33 ft) for a total 40 m (132 ft) (2).
OARSI - 40m Fast Paced Walk
Time frame: 6 week (removed due to COVID)
A fast-paced walking test that is timed over 4 x 10m (33 ft) for a total 40 m (132 ft) (2).
OARSI - 40m Fast Paced Walk
Time frame: 12 week (removed due to COVID)
A fast-paced walking test that is timed over 4 x 10m (33 ft) for a total 40 m (132 ft) (2).
OARSI - stair ascent
Time frame: Baseline (removed due to COVID)
The time (in seconds) it takes to ascend and descend a flight of stairs (2-6). The number of stairs will depend on individual environmental situations. Where possible, the 9-step stair test with 20cm (8 inch) step height and handrail is recommended.
OARSI - stair ascent
Time frame: 6 week (removed due to COVID)
The time (in seconds) it takes to ascend and descend a flight of stairs (2-6). The number of stairs will depend on individual environmental situations. Where possible, the 9-step stair test with 20cm (8 inch) step height and handrail is recommended.
OARSI - stair ascent
Time frame: 12 week (removed due to COVID)
The time (in seconds) it takes to ascend and descend a flight of stairs (2-6). The number of stairs will depend on individual environmental situations. Where possible, the 9-step stair test with 20cm (8 inch) step height and handrail is recommended.
KOOS-PS (Physical Function Shortform)
Time frame: 6 week
Scoring: Never/none=0, Monthly/mild=1, Weekly/moderate=2, Daily/severe=3, Always/extreme=4. Calculate the mean score for the 11 items, and divide by the maximum possible score for each item (i.e. 4). Traditionally in orthopedics, 100 indicates no problems and 0 indicates extreme problems. The normalized score is transformed to meet this standard. Please use the formula provided below. 100 - [(mean score PF1-PF11)/4 *100]
KOOS-PS (Physical Function Shortform)
Time frame: Baseline
Scoring: Never/none=0, Monthly/mild=1, Weekly/moderate=2, Daily/severe=3, Always/extreme=4. Calculate the mean score for the 11 items, and divide by the maximum possible score for each item (i.e. 4). Traditionally in orthopedics, 100 indicates no problems and 0 indicates extreme problems. The normalized score is transformed to meet this standard. Please use the formula provided below. 100 - [(mean score PF1-PF11)/4 *100]
KOOS-PS (Physical Function Shortform)
Time frame: 12 week
Scoring: Never/none=0, Monthly/mild=1, Weekly/moderate=2, Daily/severe=3, Always/extreme=4. Calculate the mean score for the 11 items, and divide by the maximum possible score for each item (i.e. 4). Traditionally in orthopedics, 100 indicates no problems and 0 indicates extreme problems. The normalized score is transformed to meet this standard. Please use the formula provided below. 100 - [(mean score PF1-PF11)/4 *100]
KOOS-Quality of life subscale (QoL)
Time frame: Baseline
The KOOS's five patient-relevant dimensions are scored separately: Pain (nine items); Symptoms (seven items); ADL Function (17 items); Sport and Recreation Function (five items); Quality of Life (four items). A Likert scale is used and all items have five possible answer options scored from 0 (No problems) to 4 (Extreme problems) and each of the five scores is calculated as the sum of the items included. Scores are transformed to a 0-100 scale, with zero representing extreme knee problems and 100 representing no knee problems as common in orthopaedic scales and generic measures. Scores between 0 and 100 represent the percentage of total possible score achieved.
KOOS-Quality of life subscale (QoL)
Time frame: 6 week
The KOOS's five patient-relevant dimensions are scored separately: Pain (nine items); Symptoms (seven items); ADL Function (17 items); Sport and Recreation Function (five items); Quality of Life (four items). A Likert scale is used and all items have five possible answer options scored from 0 (No problems) to 4 (Extreme problems) and each of the five scores is calculated as the sum of the items included. Scores are transformed to a 0-100 scale, with zero representing extreme knee problems and 100 representing no knee problems as common in orthopaedic scales and generic measures. Scores between 0 and 100 represent the percentage of total possible score achieved.
KOOS-Quality of life subscale (QoL)
Time frame: 12 week
The KOOS's five patient-relevant dimensions are scored separately: Pain (nine items); Symptoms (seven items); ADL Function (17 items); Sport and Recreation Function (five items); Quality of Life (four items). A Likert scale is used and all items have five possible answer options scored from 0 (No problems) to 4 (Extreme problems) and each of the five scores is calculated as the sum of the items included. Scores are transformed to a 0-100 scale, with zero representing extreme knee problems and 100 representing no knee problems as common in orthopaedic scales and generic measures. Scores between 0 and 100 represent the percentage of total possible score achieved.
Numerical Rating Scale (NRS)
Time frame: Baseline
patient to rate their pain on a defined scale. For example, 0-10 where 0 is no pain and 10 is the worst pain imaginable
Numerical Rating Scale (NRS)
Time frame: 6 week
patient to rate their pain on a defined scale. For example, 0-10 where 0 is no pain and 10 is the worst pain imaginable
Numerical Rating Scale (NRS)
Time frame: 12 week
patient to rate their pain on a defined scale. For example, 0-10 where 0 is no pain and 10 is the worst pain imaginable
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Sep 2021.
- Individual participant dataSharing planned: No
Related trials for Osteoarthritis, Knee
Not yet recruiting
Holistic Healing for Knee Osteoarthritis
Knee Osteoarthritis (Knee OA)
Recruiting
Effect of Anti-inflammatory Diet in Osteoarthritis
Osteoarthritis, Knee
Active, not recruitingPhase 2/3
Single vs Triple Hyaluronic Acid in Knee Osteoarthritis
Osteoarthritis, Knee
Not yet recruiting
The Feasibility of a Virtual/Home-based OA Treatment Program in Older Adults With OA and Multimorbidity
Osteoarthritis of the Knee
RecruitingObservational study
Exploring Factors Linked to Worsening Over Time in People With Early-stage Knee Osteoarthritis and Those With Prior Proven Acute Knee Injury.
Knee Osteoarthritis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Sara C DePaoli study director
ROC Foundation
Timothy J Bray, MD principal investigator
ROC Foundation
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Triamcinolone acetonide extended-release injectable suspension and Betamethasone sodium phosphate and betamethasone acetate Injectable Suspension in people with Osteoarthritis, Knee, run by ROC Foundation at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 20 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 27 Sep 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
OARSI - 30-second Chair Stand (time frame: Baseline (removed due to COVID)). The study lists 18 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Sep 2021.